{"filings":[{"id":2024916,"accession_number":"0001193125-26-330644","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2026-08-03T20:24:23+00:00","items":["2.02","9.01"],"status":"ready","headline":"CRISPR Q2 CASGEVY revenue $76M (+151% YoY); FDA expands approval to children 2+","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["CASGEVY Q2 revenue $76M, up 78% QoQ and 151% YoY; FDA approved for children 2+ with SCD/TDT, adding ~5,500 eligible patients.","Initiated Phase 1 trials for CTX340 (refractory hypertension) and CTX460 (alpha-1 antitrypsin deficiency) using in vivo LNP delivery.","Cash $2.36B at June 30, 2026, up from $1.98B at Dec 31, 2025, boosted by $585M convertible note issuance.","Net loss narrowed to $91.2M from $208.5M in Q2 2025, driven by lower acquired IPR&D and higher CASGEVY revenue.","Phase 1b update for CTX310 (ANGPTL3) expected at ESC Congress Aug 28; Phase 2 for CTX611 (FXI siRNA) ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":862477,"accession_number":"0001193125-26-257593","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2026-06-04T20:45:20+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"CRSP shareholders approve 2026 equity plan, re-elect all directors at AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved 2026 Stock Option and Incentive Plan, reserving shares from prior 2018 plan plus forfeited awards.","All 11 director nominees re-elected; Samarth Kulkarni re-elected chairman. Ali Behbahani received 35.5M for vs 13.2M against.","Amendments to articles of association approved, effective June 5, 2026 upon registration in Zug commercial register.","Ernst & Young AG and Ernst & Young LLP re-elected as statutory auditor and independent registered public accounting firm for FY2026.","Binding votes passed for board and executive compensation; equity grant for executive committee received ~69% support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94593,"accession_number":"0001193125-26-204147","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CRISPR Q1 2026: net loss narrows to $122.9M; CASGEVY revenue $43M; cash at $2.44B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $122.9M vs $136.0M in Q1 2025; R&D spend $68.6M, G&A $17.2M.","CASGEVY revenue of $43M; collaboration expense net $45.9M, down on higher revenue share.","Cash, equivalents and securities $2,441.8M, up from $1,975.8M, boosted by $585.4M convertible note.","Zugo-cel started 3rd Phase 1 in autoimmune neurology; SLE patients remain in DORIS remission at Month 12 and Month 6.","In vivo CTX310 IND cleared for US; CTX460 (AATD) and CTX340 (hypertension) on track for mid-2026 and H1 2026 clinical starts."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":1458000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107093,"accession_number":"0001193125-26-108333","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"CRISPR Therapeutics completes $600M convertible note offering due 2031","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $600M aggregate principal of Convertible Senior Notes due 2031; net proceeds ~$585.2M.","Effective coupon 1.125%; increased to 1.7308% due to anticipated Swiss withholding tax.","Initial conversion price ~$76.56 per share, a 45% premium to the $52.80 closing price on March 10, 2026.","Notes mature March 1, 2031; unregistered, sold to QIBs under Rule 144A; proceeds for general corporate purposes.","Holders may convert at any time before maturity; company may redeem after March 6, 2029 if stock price condition met."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107092,"accession_number":"0001193125-26-101073","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CRISPR Therapeutics prices $550M convertible notes due 2031 at 1.125% coupon","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Aggregate principal amount upsized from $350M to $550M; net proceeds estimated at ~$536.3M.","Notes mature March 1, 2031; effective coupon 1.125% (1.7308% after Swiss withholding adjustment).","Initial conversion price ~$76.56 per share, a 45% premium over $52.80 closing price on March 10, 2026.","Holders may convert at any time prior to maturity; company may redeem after March 6, 2029 under certain conditions.","Proceeds for general corporate purposes; closing expected March 16, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107091,"accession_number":"0001193125-26-048873","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CRISPR Therapeutics Q4 2025 net loss $130.6M; CASGEVY Q4 revenue $54M, full year $116M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $130.6M in Q4 2025 vs $37.3M loss in Q4 2024; collaboration expense increased to $53.7M.","CASGEVY revenue $54M in Q4, $116M full year 2025; 64 patients infused during the year (30 in Q4).","Cash, cash equivalents and marketable securities $1,975.8M as of Dec 31, 2025, vs $1,903.8M Dec 31, 2024.","R&D expenses $83.5M (Q4 2025) vs $71.7M (Q4 2024); G&A $18.4M vs $18.1M.","Pediatric CASGEVY submissions for ages 5-11 expected H1 2026; in vivo programs CTX460 (mid-2026) and CTX340 (H1 2026) to enter clinic."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":3510000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107090,"accession_number":"0001193125-26-009880","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CRISPR Therapeutics provides pipeline update: CTX310 advances to Phase 1b; zugo-cel shows durable remission in SLE","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CTX310 (ANGPTL3) advanced to Phase 1b for severe hypertriglyceridemia and refractory hypercholesterolemia after positive Phase 1 data.","CTX320 (LPA) showed up to 73% reduction in dose escalation; next-gen CTX321 with ~2-fold greater potency in preclinical testing.","Zugo-cel (CTX112): first SLE patient in drug-free DORIS remission at month 9; second SLE patient with SLEDAI-2K 0 at month 2.","Collaboration with Eli Lilly to evaluate zugo-cel + pirtobrutinib in aggressive B-cell lymphomas.","Next-gen diabetes candidate CTX213 progressing towards clinic after promising CTX211 data showing C-peptide at 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123431,"accession_number":"0001193125-25-273329","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CRISPR Therapeutics Q3 net loss widens to $106M; CASGEVY momentum builds, CTX310 Phase 1 data positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $106.4M vs $85.9M YoY; cash & equivalents $1.94B (flat vs Dec 2024).","CASGEVY: 165 patients completed cell collection, 39 infused; Vertex expects >$100M revenue in 2025.","CTX310 Phase 1 data at AHA/NEJM show durable TG and LDL reduction; advancing to Phase 1b.","CTX460 (SyNTase) preclinical data >90% mRNA correction in AATD; trial planned mid-2026.","SRSD107 Phase 2 first patient dosed for thromboembolic disorders; trial expanded in Europe."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":2646000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123430,"accession_number":"0001193125-25-240282","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2025-10-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CRISPR Therapeutics files $600M ATM offering through Jefferies","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Filed prospectus supplement to sell up to $600M of common shares at-the-market.","Offering uses existing shelf registration (Form S-3ASR filed Aug 5, 2024).","Jefferies LLC acts as sole sales agent; shares sold at company's discretion.","Legal opinion of Walder Wyss AG filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140095,"accession_number":"0000950170-25-102027","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CRISPR Therapeutics Q2 net loss $208.5M; CASGEVY hits 75 ATCs, 115 cell collections; CTX310 shows 86% LDL reduction","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $208.5M in Q2 2025 vs $126.4M in Q2 2024; cash & securities $1.72B down from $1.90B at end-2024.","CASGEVY momentum: >75 authorized treatment centers activated, ~115 patients had cells collected, 29 received infusions (16 in Q2).","CTX310 Phase 1 data: dose-dependent TG reduction up to 82% and LDL reduction up to 86% after single administration; full data H2 2025.","EMA authorized Phase 2 trial for SRSD107 (Factor XI siRNA) in thromboembolic disorders; $25M upfront to partner Sirius Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":1757000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157748,"accession_number":"0000950170-25-090170","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CRISPR Therapeutics reports up to 86% LDL reduction with CTX310; delays CTX320 data to H1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CTX310 Phase 1 shows up to 82% TG and 86% LDL reductions at 0.8 mg/kg with stable liver enzymes.","CTX320 (LPA gene) Phase 1 data update expected in first half of 2026 due to strategic pause for Lp(a) landscape insights.","CTX340 (AGT gene) for refractory hypertension advancing through IND/CTA-enabling studies.","CTX310 trial enrolling HoFH, severe hypertriglyceridemia, HeFH, and mixed dyslipidemia patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157747,"accession_number":"0000950170-25-083799","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"CRISPR Therapeutics shareholders elect new director, approve board size increase at 2025 AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New director Briggs W. Morrison, M.D. elected; board size maximum increased.","Binding votes on executive compensation approved with significant against votes (e.g., equity grant for execs: 31.8M for, 9.0M against).","Non-binding advisory vote on named executive officer compensation passed with 29.1M for vs 11.7M against.","Shareholders approved amendments to articles of association, effective June 6, 2025, subject to Swiss registration.","All director nominees re-elected; auditors Ernst & Young re-elected for FY2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157746,"accession_number":"0000950170-25-074428","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"CRISPR Therapeutics enters collaboration with Sirius on FXI-targeting siRNA; positive Phase 1 data","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront consideration: $70M in common shares + $25M cash to Sirius for co-development of FXI-targeting siRNA SRSD107.","Potential milestones: up to $340M for opt-out and up to $87.5M for development/regulatory; royalties mid-single to low-double digit.","Phase 1: single doses well tolerated, >93% reduction in FXI levels and activity, sustained up to six months post-dosing.","Phase 2 trial initiated for prevention of venous thromboembolism in patients undergoing total knee arthroplasty.","Company has options to exclusively license Sirius siRNA technology for up to two additional targets; $10M option fee per target."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157745,"accession_number":"0000950170-25-064435","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CRISPR Therapeutics Q1 2025 net loss $136M; CTX310 Phase 1 shows up to 82% TG reduction","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $136.0M in Q1 2025, compared to $116.6M in Q1 2024; cash & equivalents $1.86B.","CTX310 Phase 1 data: dose-dependent reductions in LDL (up to 81%) and TG (up to 82%) with well-tolerated safety.","CASGEVY: >65 authorized treatment centers activated; ~90 patients with first cell collection; new initiations to grow in 2025.","R&D expenses $72.5M, G&A $19.3M; collaboration expense net $57.5M (driven by CASGEVY and in vivo HSC editing).","CTX320 (Lp(a)) dose escalation ongoing with update expected Q2 2025; CTX112/CTX131 CAR T updates mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":865000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176114,"accession_number":"0000950170-25-045232","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CRSP COO Julianne Bruno steps down effective April 11, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Julianne Bruno resigns as COO of CRISPR Therapeutics to pursue external opportunities.","Departure effective April 11, 2025; she remains an employee until that date.","Resignation not the result of any disagreement with the company.","CEO Samarth Kulkarni thanked Bruno for six years of leadership in hematology and oncology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176113,"accession_number":"0000950170-25-017879","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CRISPR Therapeutics Q4 net loss $37.3M; cash at $1.9B; 50+ ATCs activated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net loss of $37.3M vs net income of $89.3M in Q4 2023.","Cash, cash equivalents, and marketable securities of $1,903.8M, up from $1,695.7M a year earlier.","Over 50 authorized treatment centers activated globally for CASGEVY; >50 patients have had cells collected.","R&D expenses fell to $82.2M in Q4 2024 from $95.1M in Q4 2023.","Pipeline catalysts in 2025: CTX112 updates mid-2025; CTX310/320 updates H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":37314000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193020,"accession_number":"0000950170-24-121103","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CRISPR reports Q3 net loss $85.9M; CASGEVY now approved in Switzerland and Canada","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $85.9M in Q3 2024 vs $112.2M loss in Q3 2023; cash and securities $1.935B as of Sept 30.","CASGEVY approved for SCD and TDT in Switzerland and Canada; 45 ATCs activated globally.","Approximately 40 patients have had cell collections across all regions as of mid-October.","CTX112 Phase 1 data to be presented at ASH 2024: 67% ORR, 44% CRR in lymphoma patients.","R&D expenses $82.2M (down from $90.7M); collaboration expense net $11.2M (down from $23.4M)."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":1623000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209390,"accession_number":"0000950170-24-090727","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CRISPR Therapeutics Q2 2024 net loss widens to $126.4M; CASGEVY launch with 35+ ATCs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $126.4M vs $77.7M in Q2 2023; R&D expenses down to $80.2M from $101.6M.","Cash, equivalents and securities $2.01B as of June 30, up from $1.70B at Dec 31, 2023.","CASGEVY: >35 ATCs activated globally; ~20 patients have had cells collected as of mid-July.","CTX112 CD19 CAR T Phase 1/2 trial opened for SLE; preliminary oncology data expected this year.","Appointed Naimish Patel as CMO; promoted Julianne Bruno to COO and Susan Kim to SVP IR."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":1021000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227401,"accession_number":"0000950170-24-067660","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"CRISPR Therapeutics shareholders approve 1M share increase to equity plan, elect two new directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment to 2018 Stock Option Plan adding 1,000,000 common shares to reserve approved (34.3M for, 8.5M against).","Sandesh Mahatme and Christian Rommel elected as new Board members; all incumbent directors re-elected.","Articles of Association amended: capital band increased to CHF 3,100,452; equity/pension practices updated.","Binding vote on Board equity grants passed 32.2M for vs 10.7M against; 2023 compensation report endorsed non-binding.","Proposal to transact other business was rejected (21.9M against, 20.3M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227400,"accession_number":"0000950123-24-005877","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CRISPR Therapeutics appoints Julianne Bruno as COO effective May 23, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bruno previously SVP and Head of Programs & Portfolio; led hemoglobinopathy partnership with Vertex.","Annual salary of $460,000, target bonus 45% of base, and eligible for equity plans.","Received one-time grant of 20,000 RSUs vesting over 4 years (25% annually).","Employment agreement provides 6-month notice period; 12-month notice and accelerated vesting after change in control.","Bruno holds MBA from Wharton, AB from Princeton; prior McKinsey biotech practice leader."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227399,"accession_number":"0000950170-24-055689","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CRISPR Therapeutics Q1 net loss widens to $116.6M; cash $2.1B after $280M offering and $200M milestone","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $116.6M in Q1 2024 vs $53.1M in Q1 2023; R&D expenses fell 24% to $76.2M.","Ended March with $2.1B cash; includes $280M February direct offering and $200M CASGEVY milestone from Vertex.","CASGEVY now approved in 5 regions; over 25 ATCs activated globally, multiple patients have cells collected.","Next-gen CAR T CTX112 (CD19) and CTX131 (CD70) trials ongoing; preliminary CTX112 data expected this year.","New in vivo programs CTX340 (hypertension) and CTX450 (porphyria) enter IND-enabling studies; clinical trials targeted for H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":504000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246269,"accession_number":"0000950170-24-017568","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CRISPR Therapeutics 2023: CASGEVY approved in 5 countries; Q4 net income $89.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["CASGEVY (exa-cel) approved in U.S., EU, Great Britain, Bahrain, KSA for SCD and TDT; ~35,000 patients in U.S. and Europe.","Q4 net income $89.3M vs net loss $110.6M in Q4 2022; cash $1.7B at year-end, pro-forma >$2.1B after $200M milestone and $280M offering.","Clinical trials ongoing for next-gen CAR T (CTX112, CTX131) and in vivo programs (CTX310, CTX320); CTX112 trial in SLE planned H1 2024.","R&D expenses $95.1M in Q4 (down from $103.6M), G&A $16.5M (down from $21.2M); collaboration expense net $20M.","Vertex paid $170M in 2023 milestones; eligible for additional $160M milestones plus royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":371206000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246268,"accession_number":"0001193125-24-033973","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"CRISPR Therapeutics to raise ~$280M via sale of 3.9M common shares at $71.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issues 3,916,082 common shares at $71.50 per share to institutional investors.","Gross proceeds of approximately $280 million; offering not underwritten, direct to investors.","Shares offered under existing shelf registration statement (Form S-3, filed July 2021).","Closing expected within ten trading days after February 13, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246267,"accession_number":"0001193125-24-032825","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CRISPR Therapeutics' CASGEVY receives EU conditional approval for sickle cell disease and beta thalassemia","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["European Commission granted conditional marketing authorization for CASGEVY (exa-cel).","Indicated for patients 12+ with severe sickle cell disease or transfusion-dependent beta thalassemia.","Eligible when HSCT is appropriate and no HLA-matched related donor is available.","CMA valid for one year, renewable annually with ongoing data review.","CASGEVY is a CRISPR/Cas9 gene-edited therapy jointly developed with Vertex."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246266,"accession_number":"0000950170-24-004616","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2024-01-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA approves CRISPR's CASGEVY for transfusion-dependent beta thalassemia in patients 12+","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["U.S. FDA approved CASGEVY (exagamglogene autotemcel) on Jan 16, 2024 for transfusion-dependent beta thalassemia in patients 12 years and older.","CASGEVY is a CRISPR/Cas9 gene-edited cell therapy developed by CRISPR Therapeutics.","The approval expands treatment options for patients with transfusion-dependent beta thalassemia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263709,"accession_number":"0000950170-23-071505","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2023-12-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CRISPR Therapeutics CMO Phuong Khanh Morrow resigns effective Jan 26, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Morrow stepped down as Chief Medical Officer on Dec 14, 2023, effective Jan 26, 2024.","Resignation is not due to any disagreement with the company.","No successor or interim CMO has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263708,"accession_number":"0000950170-23-070582","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2023-12-15T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CHMP positive opinion for CASGEVY conditional EU approval in sickle cell and beta thalassemia","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["EMA's CHMP adopted positive opinion for conditional approval of CASGEVY (exagamglogene autotemcel) for severe sickle cell disease and transfusion-dependent beta thalassemia.","CASGEVY is a CRISPR/Cas9 gene-edited therapy jointly developed by CRISPR Therapeutics and Vertex Pharmaceuticals.","European Commission decision expected in February 2024; conditional marketing authorizations are valid one year, renewable annually."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263707,"accession_number":"0000950170-23-069892","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2023-12-13T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"CRISPR amends Vertex collaboration on exa-cel; $20M contingent payment, cost deferral adjustments","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CRISPR agrees to pay Vertex $20M contingent payment upon specified event under Amendment No. 1 for exa-cel.","Deferral of CRISPR's share of costs capped at $25M annually; amounts offset against future exa-cel profitability.","Amendment allocates costs from a new third-party license agreement entered by Vertex; some details redacted.","Changes timing and portion of CRISPR's permitted cost deferrals under certain specified circumstances."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263706,"accession_number":"0000950170-23-068974","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2023-12-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA approves first CRISPR therapy, CASGEVY; Vertex to pay CRSP $200M milestone","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved CASGEVY (exagamglogene autotemcel) for sickle cell disease in patients 12+ with recurrent vaso-occlusive crises.","Vertex set wholesale acquisition cost at $2.2 million for CASGEVY in the U.S.","Approval triggered Vertex's $200 million milestone payment to CRISPR Therapeutics under the joint development agreement.","This is the first-ever FDA approval of a CRISPR-based gene-editing therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263705,"accession_number":"0000950170-23-067774","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2023-12-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CRISPR Therapeutics updates on CAR T pipeline; shifts focus to CTX112/CTX131, CTX110 Part B shows 23% 6-month CR","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Next-generation candidates CTX112 (CD19) and CTX131 (CD70) incorporate knock-out of Regnase-1 and TGFBR2 to enhance potency.","Emerging data show CTX112 and CTX131 achieve significantly higher CAR T expansion and functional persistence in patients vs. first-gen.","CTX110 Phase 1/2 Part B reported increased 6-month complete response rate of 23%, up from 19% in Part A.","Company will transition CTX110 and CTX130 patients to long-term follow-up; CTX112 and CTX131 trials ongoing.","Internal GMP facility manufacturing CTX112 and CTX131 for clinical trials; manufacturing robustness improved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263704,"accession_number":"0000950170-23-064341","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2023-11-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CRISPR/VERTEX get UK conditional approval for CASGEVY in sickle cell & beta thalassemia","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CASGEVY (exagamglogene autotemcel) received conditional marketing authorization from UK MHRA.","Approved for patients 12+ with sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.","Authorization requires no human leukocyte antigen matched related donor; valid for one year, renewable annually.","CRISPR and partner Vertex jointly developed the CRISPR/Cas9 gene-edited therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263703,"accession_number":"0000950170-23-059461","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CRISPR Q3 net loss narrows; exa-cel PDUFA: Dec 8 (SCD) & Mar 30, 2024 (TDT)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["PDUFA target action date for exa-cel in sickle cell disease: Dec 8, 2023; for beta thalassemia: March 30, 2024.","Net loss narrowed to $112.2M in Q3 2023 from $174.5M in Q3 2022; cash $1.74B.","R&D expenses decreased to $90.7M from $116.6M; G&A down to $18.3M from $27.0M.","Initiated Phase 1 trial for CTX310 targeting ANGPTL3; CTX320 on track for clinic in H1 2024.","Proposed election of Sandy Mahatme to Board at 2024 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":170000000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280919,"accession_number":"0000950170-23-046889","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2023-09-07T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"CRISPR Therapeutics President & Chairman Novak to resign Sept 15; CEO Kulkarni to become Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rodger Novak resigns as President and Chairman, effective September 15, 2023; no dispute or disagreement cited.","Samarth Kulkarni, Ph.D., CEO, appointed Chairman of the Board effective same date; will continue as CEO.","Novak co-founded CRISPR nearly 10 years ago, was instrumental in key collaborations and exa-cel development.","Kulkarni's compensation arrangement remains unchanged; Board thanks Novak for his leadership.","CRISPR's exa-cel for sickle cell disease and beta thalassemia is under regulatory review for potential first CRISPR-based medicine approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280918,"accession_number":"0000950170-23-039057","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CRISPR Q2 2023 net loss $77.7M; FDA accepts exa-cel BLAs with PDUFA Dec 8 for SCD","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA accepted BLAs for exa-cel: Priority Review for SCD (PDUFA Dec 8, 2023), Standard Review for TDT (Mar 30, 2024).","Net loss narrowed to $77.7M from $185.8M YoY; collaboration revenue $70M from Vertex milestone.","Cash and accounts receivable $1,843M; R&D spend $101.6M, down from $123.2M Q2 2022.","Vertex licensing: $100M upfront received, $70M milestone receivable, up to $230M additional milestones.","Pipeline: CTX110/130/112/131 trials ongoing; in vivo CTX310 (ANGPTL3) enters clinic in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":170000000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299586,"accession_number":"0000950170-23-027277","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"CRISPR Therapeutics shareholders approve 1.7M share increase to stock plan, capital band, board reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2018 Stock Plan increasing share reserve by 1.7M shares (including incentive stock options).","Capital band introduced, authorizing Board to increase share capital until June 8, 2028, replacing authorized capital.","Maximum Board size reduced; articles amended to comply with revised Swiss corporate law.","Compensation votes saw significant opposition: equity grants for exec committee had 14.1M votes against (34% of votes cast excluding broker non-votes).","Proposal to allow Board to handle other business was rejected by shareholders (23.9M against vs 17.5M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299585,"accession_number":"0000950170-23-027129","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA accepts exa-cel BLAs; pivotal trials meet primary endpoints in SCD and TDT","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Priority Review for SCD (PDUFA Dec 8, 2023) and Standard Review for TDT (PDUFA Mar 30, 2024).","In TDT, 24/27 (88.9%) achieved transfusion-independence ≥12 months; mean duration 20.5 months.","In SCD, 16/17 (94.1%) achieved freedom from vaso-occlusive crises ≥12 months; mean duration 18.7 months.","Safety profile consistent with busulfan conditioning; no deaths or discontinuations related to exa-cel.","Data from 83 patients (48 TDT, 35 SCD) with follow-up up to 43.7 months presented at EHA 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299584,"accession_number":"0000950170-23-018790","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CRISPR Therapeutics reports Q1 net loss of $53.1M; exa-cel submissions complete in US, EU, UK","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $100.0M from Vertex upfront; net loss improved to $53.1M vs $179.2M in Q1 2022.","Cash and securities $1,889.5M; R&D expenses $99.9M, G&A $22.4M.","Completed rolling BLAs for exa-cel in SCD and TDT; EMA and MHRA submissions validated.","Initiated clinical trials for next-gen CAR T candidates CTX112 (CD19) and CTX131 (CD70).","Appointed Raju Prasad as CFO; Brad Bolzon left board; Vertex deal includes $100M upfront and up to $230M milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":100000000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299583,"accession_number":"0000950170-23-011476","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2023-04-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CRISPR and Vertex complete rolling BLA submission to FDA for exa-cel for SCD and TDT","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Completed rolling Biologics License Applications for exa-cel for sickle cell disease and transfusion-dependent beta thalassemia.","Requests Priority Review; if granted, FDA review shortened to 8 months vs 12.","Supported by Phase 3 data from CLIMB-111, CLIMB-121, and long-term follow-up CLIMB-131.","EU and UK filings submitted Dec 2022, validated by EMA and MHRA in Jan 2023.","Exa-cel has RMAT, Fast Track, Orphan Drug, and Rare Pediatric Disease designations from FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319712,"accession_number":"0000950170-23-010439","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2023-03-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CRISPR Therapeutics board member Brad Bolzon resigns after nearly a decade","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brad Bolzon, Chairman and Managing Director of Versant Ventures, resigned from CRISPR Therapeutics board effective March 28, 2023.","Resignation was not due to any dispute or disagreement with the company or its board.","Bolzon served nearly a decade and was instrumental in defining the company's vision and strategy since its founding.","No replacement named; company expressed gratitude for his contributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319711,"accession_number":"0000950170-23-009861","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2023-03-27T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"CRISPR Therapeutics licenses CRISPR/Cas9 to Vertex for $100M upfront; eligible for $230M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Vertex pays $100M upfront for non-exclusive rights to CRISPR/Cas9 for hypoimmune cell therapies in type 1 diabetes.","CRISPR eligible for up to $230M in research and development milestones plus low-to-mid single-digit royalties.","Vertex's existing T1D programs VX-880 and VX-264 are not included; CRISPR retains ViaCyte collaboration.","Agreement expands existing relationship; Phase 1/2 study of VCTX211 (gene-edited stem cell therapy) is ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319710,"accession_number":"0000950170-23-007716","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2023-03-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CRISPR Therapeutics appoints Raju Prasad as CFO, replaces Brendan Smith","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Raju Prasad, Ph.D., appointed CFO effective March 14, 2023; previously Partner at William Blair.","Annual salary $465,000, target bonus 45%, option grant for 100,000 shares, RSU grant for 40,000 shares.","Brendan Smith resigned as CFO effective March 13, 2023; no disagreement on financial reporting.","Smith remains employee through March 31, 2023, with continued equity vesting.","Prasad receives $100,000 one-time payment, forfeitable if terminated for cause before March 14, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319709,"accession_number":"0000950170-23-003436","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2023-02-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CRISPR Therapeutics reports FY2022 net loss of $650.2M; exa-cel regulatory submissions complete in Europe","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities were $1,868.4M as of Dec 31, 2022, down from $2,379.1M a year ago.","R&D expenses for FY2022 were $461.6M, up from $340.6M in FY2021, driven by pipeline advancement.","Net loss for FY2022 was $650.2M, compared to net income of $377.7M in FY2021, due to lower collaboration revenue.","Regulatory submissions for exa-cel (CTX001) completed in Europe; U.S. BLA rolling submission on track for Q1 2023.","Enrolling and dosing ongoing for CTX110 (CD19+ B-cell malignancies) and CTX130 (CD70+ T cell lymphomas); next-gen CAR T trials initiating."],"consensus_eps_estimate":null,"consensus_eps_actual":-8.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":1198000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337934,"accession_number":"0000950170-22-020834","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CRISPR Q3 net loss $174.5M; exa-cel rolling FDA review starts Nov, EMA/MHRA by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["CRISPR Q3 net loss $174.5M, cash $1.97B; R&D spend up to $116.6M.","Exa-cel rolling FDA review starts Nov; complete submission due Q1 2023; EMA/MHRA submissions by year-end.","CTX112 (next-gen CAR-T) IND cleared; Phase 1 expected H1 2023.","VCTX211 (T1D stem-cell therapy) CTA cleared by Health Canada.","CTX110 pivotal trial ongoing; CTX130 RMAT designation for CTCL; additional data expected in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":1192000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337933,"accession_number":"0000950170-22-020257","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2022-10-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CRISPR Therapeutics COO Lawrence Klein resigns; search for successor underway","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["COO Lawrence Klein, Ph.D., resigns effective Oct 27, 2022; will stay through year-end for transition.","CEO Samarth Kulkarni thanked Klein for seven years of contributions to strategy and leadership.","Company is conducting a search to find a successor for the COO role.","Klein cited exa-cel poised for regulatory filing and five other clinical programs as company strengths."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355277,"accession_number":"0000950170-22-018864","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2022-09-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA grants rolling review for CRISPR/Vertex exa-cel; submissions planned Q4 2022 / Q1 2023","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted rolling review for exa-cel BLA for sickle cell disease and transfusion-dependent beta thalassemia.","BLA submission starts November 2022; completion expected by end of Q1 2023.","EMA and MHRA submissions on track for submission by end of 2022.","Exa-cel holds FDA RMAT, Fast Track, Orphan Drug designations; EMA PRIME and Orphan Drug."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355276,"accession_number":"0000950170-22-015255","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CRISPR Q2 net loss $185.8M; exa-cel on track for EU/UK regulatory filing by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $185.8M in Q2 2022 vs net income of $759.2M in Q2 2021; revenue fell to $0.2M from $900.2M due to prior-year Vertex upfront.","Cash & equivalents $2.07B as of June 30, 2022 (down from $2.38B at Dec 31, 2021); cash used for R&D and pre-commercial costs.","exa-cel: CLIMB-111/121 fully enrolled; regulatory submissions for SCD & TDT planned in Europe/UK by end of 2022; FDA discussions ongoing.","Enrollment continuing for CTX110 (CD19+), CTX130 (CD70) in solid/hematologic tumors; CTX110 data expected in 2022.","Next-gen CAR-T INDs (CTX131, CTX112) expected by year-end; VCTX211 CTA for T1D in H2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":1098000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373409,"accession_number":"0000950170-22-011912","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2022-06-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CRISPR Therapeutics Innovation Day held; no specific program data in 8-K text","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company hosted Innovation Day on June 21, 2022; selected slides filed as Exhibit 99.1.","The filing text does not reproduce slide content; no milestones, endpoints, or financial figures disclosed.","Without access to the exhibit, material program updates cannot be assessed from this filing alone.","Ticker CRSP; event reported under Item 8.01 as other material event."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373408,"accession_number":"0000950170-22-011570","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2022-06-13T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"CRISPR Therapeutics shareholders reject authorized capital increase; approve stock plan amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 10 to adjust authorized share capital and extend date for capital increase was not approved (37.0M for, 18.8M against).","Amendment to 2018 Stock Plan approved, adding 1.7M common shares for issuance under the plan.","Maria Fardis, Ph.D. elected as new board member; all nine incumbent directors re-elected.","Binding advisory votes on executive compensation approved; frequency of say-on-pay set at one year.","All other proposals passed, including re-election of auditors and independent voting representative."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373407,"accession_number":"0000950170-22-011518","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2022-06-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Exa-cel shows 95% TDT transfusion-free; CTX130 achieves 70% ORR in T-cell lymphoma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["42 of 44 TDT patients transfusion-free; all 31 SCD patients free of VOCs; follow-up up to 37.2 months.","Exa-cel primary endpoints amended: TDT target Hb ≥9 g/dL without transfusions; SCD target no severe VOCs.","Pediatric exa-cel studies CLIMB-141/151 now enrolling patients ages 5-11 with TDT or SCD.","CTX130 at DL3+: ORR 70% (30% CR) in PTCL/CTCL; 90% DCR; responses across all disease compartments.","CTX130 well tolerated: no DLTs, no GvHD, all CRS/ICANS grade 1-2; no treatment-related deaths."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373406,"accession_number":"0000950170-22-010081","cik":1674416,"company_name":"CRISPR Therapeutics AG","ticker":"CRSP","form_type":"8-K","filed_at":"2022-05-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CRISPR Therapeutics appoints Phuong Khanh Morrow, M.D., as Chief Medical Officer effective May 23, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Morrow brings over a decade of global drug development experience, most recently as VP at Amgen leading hematology/oncology.","She will lead CRISPR Therapeutics' global clinical development and regulatory operations.","CEO Samarth Kulkarni cited her expertise in oncology and track record in bringing novel medicines to patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5313363802.301328,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-05-16T23:59:59+00:00|373406"}